European equities traded in the US as American depositary receipts were trending higher late Friday morning, rising 0.62% to 1,443.18 on the S&P Europe Select ADR Index, which is up 0.36% for the week.
From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and internet browser company Opera (OPRA), which rose 5.7% and 2.8% respectively. They were followed by petroleum refiner Equinor (EQNR) and medical device maker EDAP TMS (EDAP), which were up 3.8% and 3.6% respectively.
The decliners from continental Europe were led by pharmaceutical company Ascendis Pharma (ASND) and biopharmaceutical company argenx (ARGX), which were down 2.7% and 1.4% respectively. They were followed by internet ad agency Criteo (CRTO) and pharmaceutical company Novo Nordisk (NVO), which lost 1.9% and 0.7% respectively.
From the UK and Ireland, the gainers were led by cryptocurrency company Argo Blockchain (ARBK) and telecommunications operator Vodafone Group (VOD), which advanced 6.3% and 4.2% respectively. They were followed by biopharmaceutical company Akari Therapeutics (AKTX) and pharmaceutical company Silence Therapeutics (SLN), which increased 3.2% and 1.9% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and construction materials supplier CRH (CRH), which dropped 2.4% and 2.5% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and cruise line operator Carnival (CUK), which fell 1.9% and 0.8% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.